Loading company…
Singapore-based One BioMed develops the Xceler8 Solution, an automated platform for nucleic acid extraction in research and clinical labs.
Founded in 2015 in Singapore by Mi-Kyoung Park, One BioMed Pte Ltd makes the Xceler8 Solution, an automated molecular platform for nucleic acid extraction and purification that uses a patented reversible-crosslinking method. It sells mainly to research institutions, hospitals, and laboratories in North America, Europe, and Asia. The company reported revenue of USD 13,805.50 and EBITDA of USD -2,628,601.40 in 2022. In October 2021 it raised USD 500,000 in Series A funding from new investor BK Electronics, at a post-money valuation of USD 16 million.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in